Table 23Characteristics of included placebo-controlled trials of alpha-blockers

StudyArm Dose mg/day (N)Duration (Weeks)Population Trauma TypeBaseline PTSD SeverityaMean Age (Y)% F% Non-whiteRisk of Bias
Raskind et al., 2003135Prazosin (2 to 10mg) (5)
Placebo (5)
20Male
Combat veterans
79.1 to 83.6530NRMedium
Raskind et al., 2007136Prazosin (2 to 15mg) (20)
Placebo (20)
8Male and female
Combat veterans
70.056535Medium

CAPS = Clinician Administered PTSD Scale; F = female; mg = milligram; N = total number randomized/assigned to intervention and control groups; NR = not reported; PTSD = posttraumatic stress disorder; y = year

a

Data reported are mean CAPS or range of mean CAPS scores across groups unless otherwise specified.

Note: When mean data for baseline PTSD severity were not reported for the total sample but were presented for each study arm, we provide the range across arms.

From: Results

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.